These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30319946)

  • 1. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.
    Piparva KG; Jansari G; Singh AP
    Perspect Clin Res; 2018; 9(4):165-169. PubMed ID: 30319946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
    Dela AI; Tank NKD; Singh AP; Piparva KG
    Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
    Joseph P; Desai VB; Mohan NS; Fredrick JS; Ramachandran R; Raman B; Wares F; Ramachandran R; Thomas A
    Indian J Med Res; 2011 May; 133(5):529-34. PubMed ID: 21623039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
    Mpagama SG; Mvungi HC; Mbelele PM; Semvua HH; Liyoyo AA; de Guex KP; Sloan D; Kibiki GS; Boeree M; Phillips PPJ; Heysell SK
    Pilot Feasibility Stud; 2023 Apr; 9(1):55. PubMed ID: 37005695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An epidemiological study of multi drug resistant tuberculosis cases registered under Revised National Tuberculosis Control Programme of Ahmedabad City.
    Bhatt G; Vyas S; Trivedil K
    Indian J Tuberc; 2012 Jan; 59(1):18-27. PubMed ID: 22670507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis.
    Jain K; Desai M; Solanki R; Dikshit RK
    J Pharmacol Pharmacother; 2014 Apr; 5(2):145-9. PubMed ID: 24799815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot project: 99DOTS information communication technology-based approach for tuberculosis treatment in Rajkot district.
    Thakkar D; Piparva KG; Lakkad SG
    Lung India; 2019; 36(2):108-111. PubMed ID: 30829243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
    Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
    Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multidrug resistant tuberculosis in Romania in the last years (2004-2007)--an extremely important social phenomenon].
    Marica C; Didilescu C; Chiotan D; Galie N; Tănăsescu M; Popescu-Hagen M; Popa M
    Pneumologia; 2008; 57(4):195-200. PubMed ID: 19186681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.
    Hire R; Kale AS; Dakhale GN; Gaikwad N
    Mediterr J Hematol Infect Dis; 2014; 6(1):e2014061. PubMed ID: 25237474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: A prospective study.
    Patel SV; Nimavat KB; Alpesh PB; Shukla LK; Shringarpure KS; Mehta KG; Joshi CC
    J Infect Public Health; 2016; 9(4):478-84. PubMed ID: 26724262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.